Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials.
Eur. Urol., Nov (2012)
HIF1Î± protein stability is increased by acetylation at lysine 709.
J. Biol. Chem., Oct;287(42):35496-505 (2012)
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.
Nat. Med., Sep;18(9):1359-68 (2012)
Cell membrane water exchange effects in prostate DCE-MRI.
J. Magn. Reson., May;218:77-85 (2012)
Feasibility of shutter-speed DCE-MRI for improved prostate cancer detection.
Magn Reson Med., Mar (2012)
Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
Clin Genitourin Cancer., Mar;10(1):6-14 (2012)
The Exercising Together project: design and recruitment for a randomized, controlled trial to determine the benefits of partnered strength training for couples coping with prostate cancer.
Contemp Clin Trials., Mar;33(2):342-50 (2012)
HDAC4 protein regulates HIF1Î± protein lysine acetylation and cancer cell response to hypoxia.
J. Biol. Chem., Nov;286(44):38095-102 (2011)
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naÃ¯ve prostate cancer.
Urol. Oncol., Aug (2011)
Prostate cancer and vitamin D: what does the evidence really suggest?
Urol. Clin. North Am., Aug;38(3):333-42 (2011)
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.
Sci Transl Med., Jun;3(85):85ra47 (2011)
New therapies for castration-resistant prostate cancer: efficacy and safety.
Eur. Urol., Aug;60(2):279-90 (2011)
Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.
Clin. Cancer Res., Jul;17(13):4558-67 (2011)
Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy.
Anticancer Res., Mar;31(3):973-4 (2011)
Toward predictors of survival in castration-resistant prostate cancer.
Cancer., Sep;117(17):3882-4 (2011)
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the department of defense prostate cancer clinical trials consortium.
Cancer., Dec (2010)
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.
Cancer Res., Oct;70(20):7992-8002 (2010)
Acupuncture for hot flashes in patients with prostate cancer.
Urology., Nov;76(5):1182-8 (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Lancet., Apr;375(9724):1437-46 (2010)
ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.
Cancer Res., Apr;70(8):3239-48 (2010)